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Microbiota derived short chain fatty acids promote
histone crotonylation in the colon through histone
deacetylases
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The recently discovered histone post-translational modification crotonylation connects cel-
lular metabolism to gene regulation. Its regulation and tissue-specific functions are poorly
understood. We characterize histone crotonylation in intestinal epithelia and find that histone
H3 crotonylation at lysine 18 is a surprisingly abundant modification in the small intestine
crypt and colon, and is linked to gene regulation. We show that this modification is highly
dynamic and regulated during the cell cycle. We identify class I histone deacetylases, HDAC1,
HDAC2, and HDAC3, as major executors of histone decrotonylation. We show that known
HDAC inhibitors, including the gut microbiota-derived butyrate, affect histone decrotonyla-
tion. Consistent with this, we find that depletion of the gut microbiota leads to a global
change in histone crotonylation in the colon. Our results suggest that histone crotonylation
connects chromatin to the gut microbiota, at least in part, via short-chain fatty acids and
HDACs.
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H istone post-translational modifications (HPTMs) arefundamental regulators of gene expression and are tightlycontrolled by enzymes that respond to the availability of
metabolic precursors1. Histone acetylation is a well-studied
HPTM usually linked to active genes and is added to various
lysine groups of histones by histone acetyltransferases (HATs)
and removed by histone deacetylases (HDACs). More recently,
various longer chain acylations of histones have been character-
ized, including crotonylation2, butyrylation3, 4, and hydro-
xybutyrylation5. These acylations have been linked to cellular
metabolism, because they reflect the availability of the short-chain
fatty acids (SCFAs) and their coenzyme A adducts in the cell5, 6
(reviewed in refs. 7, 8). This has been demonstrated by introdu-
cing crotonate (2-butenoate), an SCFA moiety produced
intracellularly as an intermediate of metabolic processes2, 6, 9, 10,
to the cell culture media which affects histone crotonylation
levels. Histone crotonylation reprograms the functionality of
nucleosomes, setting it apart from histone acetylation, by favoring
interactions with a specific set of chromatin modifiers9–12.
A link between cellular metabolism, SCFAs, and transcriptional
regulation is particularly relevant in the intestine where micro-
organisms break down complex carbohydrates to SCFAs such as
acetate, propionate, and butyrate13, 14. SCFAs are an important
component of normal gut physiology by providing a major
energy source for the colon epithelial cells15. They also affect
cellular functions and modulate immune responses, in part by
affecting gene expression and the epigenome through inhibiting
HDACs14, 16. Here, we explore histone crotonylation in intestinal
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Fig. 1 Histone crotonylation is found in the intestine. a Western blot analysis of whole cell extracts from several mouse tissues using indicated antibodies
shows that histone crotonylation is particularly abundant in the brain and colon; the analysis of tissues from two mice is shown. b Relative abundance of
H3K18cr in the intestinal epithelium cell fractions, n= 3, error bars are standard deviation. c, d Immunofluorescence microscopy with anti-pan crotonyl
antibody (green, left panels) and DAPI counterstaining (cyan, right panels) of a mouse colon (c) and small intestinal (d) tissue sections, scale bars 40 μm
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epithelial cells and show that histone H3 lysine 18 crotonylation
(H3K18cr) is readily detectable in this tissue and that histone
crotonylation is regulated by class I HDACs. Our findings suggest
that histone crotonylation connects chromatin structure to the
gut microbiota via HDACs and SCFAs.
Results
Histone crotonylation abundance in the intestine. Western blot
analysis of the level of histone crotonylation in several tissues
(colon, brain, liver, spleen, kidney) using the antibodies against
crotonyl-lysine and H3K18cr indicates that the greatest levels of
histone crotonylation are in colon and, interestingly, brain among
the tissues analyzed (Fig. 1a). An approximately 70 kDa protein in
the brain extract is recognized by the antibody against crotonyl-
lysine, indicating the presence of a crotonylated non-histone
protein in the brain.
To characterize the pattern of histone H3 PTMs in intestinal
cells, we analyzed small intestine epithelium, colon epithelium,
and small intestine crypt-enriched fractions by LC-MS/MS
(Supplementary Fig. 1, LC-MS: liquid chromatography-mass
spectrometry). This analysis allowed the site-specific identifica-
tion of 38 differentially modified peptides (Supplementary
Table 1). Among them, we identified lysine methylation and
acetylation combinations at several H3 peptides and increased
levels of monomethylated H3K4 in both small intestinal crypt
and colon fraction compared to the fraction from whole small
intestine epithelium. Di- and tri-methylated H3K4 were below the
detection limit, likely due to their low abundance (Supplementary
Fig. 1 and Supplementary Table 1). Most interestingly, we
identified histone lysine crotonylation at several histone H3
residues: K9, K14, K18, K27, and K56 (Table 1, Supplementary
Fig. 2, and Supplementary Table 1). H3K18 crotonylation
(H3K18cr), in association with H3K23 acetylation, was the most
abundant histone H3 crotonylation mark in crypt and colon
fractions (Fig. 1b, Supplementary Table 1), possibly suggesting
that these two marks are co-regulated. H3 crotonylation
abundance is overall rather low at K9, K27, and K56.
Representative MS/MS spectra for all crotonylated peptides are
displayed in Supplementary Fig. 2.
As immunostaining with anti-H3K18cr antibody did not work
in our hands, we performed immunostaining of murine small
intestine and colon using antibodies targeting crotonyl-lysine (anti-
Kcr) and histone H4 crotonylated at K8 (anti-H4K8cr). This
demonstrated the presence of these modifications in the nuclei of
intestinal epithelium cells, especially in the proliferative crypt
compartments (Fig. 1c, d, Supplementary Fig. 3 and 4). Western
blot analysis of in vitro crotonylated or acetylated histones and of
whole colon extracts confirmed specificity of the anti-Kcr, anti-
H3K18cr, and anti-H3K18ac antibodies (Supplementary Fig. 5a, b).
Genome-wide localization of H3K18cr in the colon epithelium.
As we found that histone H3K18cr is the most abundant histone
crotonylation mark in the intestine, we characterized it further by
chromatin immunoprecipitation-sequencing (ChIP-seq). This
analysis showed that H3K18cr is associated with transcription
start sites (TSS) (Figs. 2a–d), similar to H3K4me3 (Fig. 2c), as has
been shown before in macrophages6. To investigate the link
between H3K18cr and transcription, we performed RNA-
sequencing (RNA-seq) on colon epithelial crypts and found
higher gene expression levels associated with increased H3K18cr
enrichment over TSS (Fig. 2e). KEGG pathway analysis of genes
with high levels of H3K18cr over their TSS highlights various
pathways, in particular several involved in cancer, suggesting that
deregulation of histone crotonylation may be linked to cancer
(Fig. 2f, Supplementary Fig. 6).
Microbiota and histone crotonylation in the mouse colon. As
histone crotonylation has been linked to cellular metabolism and
we found it to be relatively abundant in the gut, we hypothesized
that this modification may be linked to the SCFAs that are gen-
erated by intestinal microbiota, especially in the colon. Treatment
of mice for 3 days with a cocktail of antibiotics led to a reduction
of the bacterial load (Suppl. Figure 7a) and a reduction of SCFAs
in colon luminal content and serum (Fig. 3a). This was linked to a
noticeable global decrease of histone crotonylation in the colon
tissue, which was particularly clear with histone H4K8 crotony-
lation but also for H3K18 and H4 crotonylation (as detected by
the anti-Kcr antibody) (Figs. 3b, c). Interestingly, we found that
the treatment with antibiotics was also linked to increased
amounts of HDAC2 (Figs. 3d, c; changes in HDAC1 and HDAC3
levels were not consistent, Supplementary Fig. 7b).
SCFAs promote histone crotonylation. Next we investigated if
the drop in SCFA concentration in the colon lumen and serum
could account for the observed global reduction in histone cro-
tonylation. When added to the media of human colon carcinoma
cells (HCT116) and mouse small intestinal organoids, the SCFA
crotonate promoted H3 and H4 crotonylation, thereby confirm-
ing previous findings6 (Fig. 4a, Supplementary Fig. 8a). We found
that histone crotonylation is highly dynamic, being increased
within 2 h of crotonate addition to the medium and lost within 1
h of wash out (Supplementary Fig. 8b). The chemically related
SCFA butyrate, which is naturally present in the intestine, also
promoted histone crotonylation at physiologically relevant con-
centrations, both in gut organoids and HCT116 cells (Fig. 4a,
Supplementary Fig. 8c). Therefore, these in vitro observations are
consistent with the idea that depletion of the microbiota leads to a
decrease in histone crotonylation of the colon epithelium because
of the drop in SCFAs.
HDAC inhibitors upregulate histone crotonylation. Since
butyrate is a well-known HDAC inhibitor17, we hypothesized that
HDACs might regulate histone crotonylation and their inhibition
explains the increase in histone crotonylation upon butyrate
Table 1 List of K-crotonyl histone-modified peptides
Modified sequences Modified sites Gene names Charge m/z RT Score
K(cr)STGGK(*)APR K9 HIST2H3 2+ 507.7921 71.3 60.3
K(*)STGGK(cr)APR K14 HIST2H3 3+ 338.8639 72.9 33.4
K(cr)QLATKAAR K18 HIST2H3 2+ 550.3367 90.8 93.1
K(cr)QLATK(ac)AAR K18 HIST2H3 2+ 548.8273 91.0 89.1
K(cr)SAPATGGVKKPHR K27 HIST2H3 3+ 531.3110 85.4 39.7
YQK(cr)STELLIR K56 HIST2H3 2+ 659.8710 129.0 47.3
Summary of identified crotonylation sites on histone H3 from the crypt fraction of the small intestine using MS/MS analysis
SI small intestine, cr crotonylation, ac acetylation, (*) chemical alkylation
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treatment. We found that other HDAC inhibitors are also able to
promote histone crotonylation in HCT116 cells, including tri-
chostatin A (TSA), the clinically relevant suberanilohydroxamic
acid (SAHA), and valproic acid (VPA, Supplementary Fig. 9).
MS275 (entinostat), a selective inhibitor of class I HDACs, which
has been tested in various clinical trials18, significantly promoted
histone crotonylation at sub-micromolar concentrations in
HCT116 cells (Fig. 4b). This outcome cannot be explained by
cross-reactivity of the anti-crotonyl antibodies to acetylated his-
tones6 (Supplementary Fig. 5). A ChIP-qPCR for H3K18cr
observed a significant increase in enrichment upon MS275
treatment in different genomic loci including repetitive regions,
suggesting that class I HDAC inhibition leads to a spread of
histone crotonylation into intergenic areas (Fig. 4c).
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To investigate how HDAC inhibitors change the distribution of
histone crotonylation over the genome, we performed ChIP-seq
analysis of H3K18cr and H3K18ac. This showed a relative
decrease of read counts over TSS when HCT116 cells were treated
with MS275 (Fig. 5a, b). This could be explained with an overall
increase of these marks over the genome outside of the TSS
regions. ChIP-seq measures the relative proportional distribution
of a mark over the genome. If the proportional increase of
H3K18cr over TSS is lower than the one outside of TSS, an
increase of histone crotonylation over regions outside of TSS
(which cover a much greater proportion of the genome than all
TSS combined) will lead to an apparent proportional drop of this
mark in TSS regions.
Interestingly, H3K18cr and H3K18ac peaks correlate highly
and occur at the same sites genome-wide in HCT116 cells, with or
without MS275 treatment (Figs. 5c–e). MS275 treatment of
HCT116 cells caused changes in gene expression, which are
linked to changes in H3K18 acetylation and crotonylation (Fig. 5f,
g). Thus, gene silencing and chromosome segregation defects
occurring upon HDAC inhibitor treatments19 may not only be
due to aberrant histone acetylation, but could also be linked to
histone crotonylation.
Histone crotonylation is linked to the cell cycle. We performed
cell cycle arrest and release experiments in presence or absence of
the class I HDAC specific inhibitor MS275. The results indicated
that histone crotonylation, including H3K18cr, is linked to cell
cycle progression, showing an increase in S and G2-M phase over
G1 arrested cells (Fig. 6, lanes 1–8). This experiment also suggests
that class I HDACs may be involved in this cell cycle-mediated
modulation of histone crotonylation levels, as the G1-arrest-
linked downregulation of histone crotonylation is inhibited in the
presence of MS275 compared to untreated cells (Fig. 6, lanes 1, 2,
9, 10). In addition, in MS275-treated cells, histone crotonylation
was modulated during the cell cycle, but levels remained generally
higher compared to untreated cells (Fig. 6, lanes 9–16).
Class I HDACs are histone decrotonylases. To test further if we
could link class I HDACs to decrotonylation, we transiently over-
expressed a fusion protein of HDAC1 with green fluorescent
protein (GFP), an N-terminal deletion mutant version of this or
GFP in HCT116 cells, sorted the transfected cells, and monitored
histone crotonylation by western blot analysis. This showed that
the over-expression of HDAC1 but not its mutant version with an
N-terminal truncation (or GFP alone) caused some reduction of
global histone H3K18 and H4K8 crotonylation (Supplementary
Fig. 10).
To validate the ability of HDACs to decrotonylate histones, we
tested this activity with recombinant, purified HDACs in in vitro
experiments and found that the class I HDAC enzymes HDAC1,
HDAC2, and the HDAC3/Ncor1 complex efficiently removed the
crotonyl moiety of in vitro crotonylated histones (Fig. 7a). Using
this in vitro approach, we estimated enzyme kinetic values for the
decrotonylation of H3K18cr and deacetylation of H3K18ac and
found that HDAC1 has a similar capacity to perform each
reaction. HDAC1 has lower Vmax and Kcat values for the
decrotonylation compared to the deacetylation reactions indicat-
ing that HDAC1 has a higher maximum turnover with the acetyl
substrate than the crotonyl substrate (Fig. 7b, Supplementary
Fig. 11). We found that the Km with acetylated histones of 1.47
µM was similar to a published Km of HDAC with a BOC-lys
(acetyl)-AMC of 3.7 µM20. Published Km values with different
fluorescent or tritiated acetyl substrates vary from 0.68 to 78
µM21–24. Relative to this, the Km of the crotonyl substrate was
lower at 0.42 µM suggesting that HDAC1 can efficiently bind
crotonylated histones at low concentrations of substrate. This
may be relevant in the context of the cell where HDAC1 could
respond to minor fluctuations in the availability of the crotonyl
substrate.
In vitro, HDAC inhibitors TSA and butyrate reduced
decrotonylation by HDAC1 significantly, demonstrating that
the HDAC inhibitors, including SCFAs, affect decrotonylation by
HDACs directly (Fig. 7c). TSA inhibited deacetylation at lower
doses (IC50 ~5 nM) than decrotonylation (IC50 ~50 nM) high-
lighting the differential impact of inhibitors on HDAC activity
and potential for specific drug development. We also found that
crotonate inhibited decrotonylation and deacetylation in vitro
(Fig. 7c). Remarkably, at crotonate concentrations of 6 mM or
higher, HDAC1 catalyzed the addition of the crotonyl moiety to
lysine groups of histones (Fig. 7d). This did not occur with acetate
or butyrate, possibly due to their lower chemical reactivity
compared to crotonate. While this finding may not be directly
biologically relevant, as it is unlikely that such high concentra-
tions of crotonate are found intracellularly, it highlights the
reversible nature of the decrotonylation reaction by HDAC1.
A previous study dismissed HDACs 1–11 as decrotonylases
based on an in vitro fluorometric assay using a peptide analog2.
We also did not find decrotonylase activity for HDAC1 using the
same assay, but found that the BOC-Lys(crotonyl)-AMC
compound used is inhibitory for the deacetylation step of the
BOC-Lys(acetyl)-AMC. This suggests that the HDACs interact
with BOC-Lys(crotonyl)-AMC, but potentially cannot release the
compound (Fig. 8). Future studies will examine to what extent
HDACs require the peptide context of histone H3 for efficient
decrotonylation activity.
Discussion
A key finding of our study is that histone crotonylation is sur-
prisingly abundant in the intestinal epithelium, especially the
crypt fraction of the small intestine and the colon. This supports
the notion that histone crotonylation does not simply reflect
‘metabolic noise’, as in the ability of p300 to use crotonyl-CoA to
modify histones, but has specific functions, which might vary
between tissues. We also find high levels of histone crotonylation
Fig. 2 H3K18cr ChIP-seq from colon epithelium analysis. ChIP-sequencing on isolated colon epithelial cells from two mice. a Browser view of a segment
from chromosome 1 showing a representative profile of the distribution of H3K18cr peaks with relationship to genes. Relative enrichment of the combined
replicate sets of ChIP and input in linear scale are shown, probes are 500 bp, 250 bp overlap. b Average distribution of ChIP-seq normalized read counts
with relation to genes shows that histone H3K18cr is highly enriched over transcription start sites (TSS) in colon epithelial cells. c Link between H3K4me3
and H3K18cr, using MACS peak quantification and an aligned probe plot. Probes were ranked according to H3K4me3 signal strength and span 5 kbp
around MACS peaks. d Average distribution of reads in linear scale with relation to genes' TSS, showing enrichment over these sites. e Relationship
between H3K18cr enrichment over TSS and mRNA levels of the corresponding genes from cells isolated from the mouse colon epithelium were quantified
using mRNA-seq (three biological replicates) and the normalized read counts over genes were divided into percentile bins as indicated, from lowly
expressed genes (0–25 percentile) to very highly expressed genes (99–100 percentile). H3K18cr over TSS ±0.5 kbp of genes belonging to the expression
bins was quantified and is shown in box-whisker plots. f KEGG pathway terms and their adjusted p-values of significance of genes with the highest 10
percentile H3K18cr associated (MACS) peaks. Only results with –log10(p)> 6 are shown, see Supplementary Fig. 6 for all results. Cancer pathways are
highlighted (red terms)
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Fig. 3 Microbiota depletion affects colonic histone crotonylation and HDAC2. Antibiotic treatment led to a decrease in luminal and serum SCFA levels in
mice (n≥ 3, from experiment 2). a Acetate, propionate, and butyrate concentrations were measured in the colon lumen and serum by gas chromatography.
Unpaired t-tests were conducted, *p-value< 0.05 and ***p-value< 0.001. Values of zero were below detectable levels. b Quantifications of western blot
analysis of colon extracts from untreated and treated mice, n≥ 3. Experiments 1 and 2 are repeat experiments. Center values (small bar) are the average of
the treatment group relative to the untreated group. Two-way ANOVA (two-tailed) was performed on quantified bands to compare the effect of treatment
for both experiments together; * corresponds to a p-value of< 0.05 and *** corresponds to <0.001. The quantification showed a statistically significant
decrease in H4 crotonylation as detected by the anti-Kcr antibody and in H4K8cr, H4K8ac, and H3K18cr levels upon antibiotics treatment. c Global
changes in various colon histone crotonylation and acetylation marks and HDAC2 as seen in representative western blots of colon extracts, from
experiment 1. d Two-way ANOVA was performed on quantified bands from western blotting analysis with anti-HDAC2. A statistically significant increase
was observed (p-value< 0.05)
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in the brain. As SCFAs are taken up from the colon into the blood
stream (as supported by our own data, Fig. 3a), SCFAs might be
taken up by brain cells, where they may affect histone mod-
ifications25. Future studies will determine if there are brain-
specific functions for histone crotonylation.
We found that the SCFA butyrate, a well-known HDAC
inhibitor, promotes histone crotonylation in intestinal cell
and organoid culture. This led us to test other HDAC inhibitors,
which showed that class I specific HDAC inhibitors
strongly promoted histone crotonylation at concentrations at
which they affected histone acetylation and implicated class I
HDACs in histone decrotonylation. Our in vitro assays of
recombinant, purified class I HDAC1-3 show that they are
decrotonylases and demonstrates that HDAC inhibitors, includ-
ing butyrate, reduce decrotonylation. Furthermore, the low Km
value of HDAC1 with crotonylated histones suggests that it can
efficiently decrotonylate this relatively less abundant histone
modification. Together, these findings strongly suggest that
SCFAs such as butyrate promote histone crotonylation by inhi-
biting the decrotonylase activity of HDACs in colon epithelial
cells. Future studies will address to what extent SCFAs also
promote crotonylation by acting as substrates for the generation
of intracellular crotonyl-CoA.
Our finding that class I specific HDAC inhibitors promoted
global histone crotonylation led us to explore where this increased
histone crotonylation (H3K18cr) occurs in the genome in cul-
tured colon carcinoma cells. We show that the increase is not
because of a greater number of crotonylation peaks but a diffuse
spread of crotonylation genome-wide, including within repetitive
regions. Therefore, while H3K18cr ‘peaks’ do exist over TSS, these
findings suggest that pervasive crotonylation also occurs across
the genome and that it is controlled by class I HDACs.
Additionally, we show that histone crotonylation is modulated
during the cell cycle and that class I HDACs play a role in this
regulation. In synchronized cells, we find an increase of histone
crotonylation during S phase which is enhanced when cells are
treated with the HDAC inhibitor MS275. Newly synthesized
histones are acetylated on several specific lysine residues (e.g., K5
and K12 on histone H4; K14, K18 on histone H3) prior to their
deposition onto nascent chromatin26, 27, reviewed in ref. 28. These
acetylations are then globally removed following nucleosome
assembly, which is important for the maintenance of repressive
chromatin, such as pericentromeric heterochromatin19, 29. Class I
HDACs are targeted to replicating chromatin and mediate this
deacetylation30, 31. Therefore, the levels of these histone acetyla-
tions are modulated in a cell cycle and HDAC-dependent man-
ner. In this study, we provide evidence that histone crotonylation
marks behave similarly to the pre-deposition acetylation marks:
they are low in G1 arrested cells and increase as cells progress
through S phase and this modulation depends on class I HDACs.
Therefore, histone crotonylation is not simply modulated through
dilution with non-crotonylated histones through the cell cycle,
but appears to be actively regulated by HDACs. Future studies
will address if histone crotonylation is also mediated prior to
histone deposition onto nascent chromatin and will address how
HDACs and other factors regulate histone crotonylation con-
comitant with chromatin replication.
Importantly, consistent with our finding that microbiota-
generated SCFAs such as butyrate promote histone crotonylation
in vitro, we show that depletion of the microbiota led to a loss of
histone crotonylation. Our data suggest that the levels of histone
crotonylation in the gut reflect the generation of SCFAs by the
microbiota. Given the important role of microbiota-generated
SCFAs in modulating immunity and metabolism, our work
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Fig. 4 Butyrate and class I HDAC inhibition promote histone crotonylation. aWestern blot analysis with indicated antibodies of whole cell extracts of small
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proposes that the signaling between the microbiota and chro-
matin might be mediated through histone crotonylation. Future
work will explore further the roles of histone crotonylation in
normal gut physiology including host–microbiome interaction,
inflammation, and disease.
A surprising finding of our work is that depletion of the
microbiota of mice with antibiotics not only led to a drop in
luminal and serum SCFAs, but also an increased expression of
HDAC2 in colon. A reduction in histone crotonylation is con-
sistent with both changes. A loss of SCFAs upon microbiota
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depletion may lead to stabilization or increased expression of
HDAC2. In this context, it is interesting to note that a previous
study has shown that the stability of HDAC2 is selectively
reduced by the HDAC inhibitor valproic acid (a branched SCFA)
or butyrate and this is mediated by Ubc8-RLIM targeted pro-
teasomal degradation32. Remarkably, HDAC2 expression has
been linked to colorectal tumorigenesis33, 34. It will be interesting
to examine how this links to our finding that H3K18cr peaks
occur over a significant number of genes linked to cancer path-
ways. Future studies will examine how HDAC2 expression,
microbiota, and SCFAs are linked and how this affects histone
crotonylation over specific genes and cancer progression in the
colon.
While our study was in revision, a study by Yu, Wong, and
collaborators also demonstrated histone decrotonylation activity
of class I HDACs using transfection experiments in cell culture35.
Our study complements and extends these and related
findings36, 37 as we explore the effect of HDAC inhibitors on the
distribution of histone crotonylation, the link between histone
crotonylation and the cell cycle, and investigate how the micro-
biota influence these processes. This expands our understanding
of the functional spectrum of these exciting drug targets in cancer
therapy and other diseases38, 39 and provides a basis for the
development of specific inhibitors of the decrotonylation versus
deacetylation activity of these enzymes.
Methods
Mice. Mice were C57BL/6 background, details available on request. Male mice were
used for all experiments. All mice were kept in specific pathogen-free conditions
and fed ad lib. Mice for the ChIP and RNA-seq experiments were housed at the
Babraham Institute Biological Service Unit. All experimental protocols at Babra-
ham Institute were approved by the Babraham Research Campus local ethical
review committee and the Home Office (PPL 80/2488 and 70/8994). The anti-
biotics treatment experiments were performed at the University of Campinas. Male
C57BL/6 mice at age 8–12 weeks were provided by the Multidisciplinary Centre for
Biological Investigation (CEIMB) and all the experimental procedures were
approved by the Ethics Committee on Animal Use of the Institute of Biology,
University of Campinas (protocol number 3742-1). No sample size calculation was
used as the minimum number of mice used was 3 or 4. Mice of the same age and
breed were randomly put in the experimental groups. The order of samples from
groups was mixed on collection. Sample size is reported in exact numbers and no
samples are excluded from the analysis. No blinding was conducted.
Antibiotic treatment of mice. Mice received 200 µl of a mixture of antibiotics (5
mg/ml of neomicin, 5 mg/ml of gentamicin, 5 mg/ml of ampicillin, 5 mg/ml of
metronidazole, and 2.5 mg/ml of vancomycin, Sigma Aldrich) daily for 3 days by
gavage. The weight of the animals was monitored throughout the experiment. At
the end of treatment period, feces were collected and snap-frozen in liquid
nitrogen. After that, the animals were anesthetized using a mix of ketamine and
xylazine (300 and 30 mg/kg, respectively) and the blood was collected by cardiac
puncture. The blood was maintained at room temperature (RT) for 30 min and
then centrifuged (3000×g, 8 min). The serum was collected and frozen at −80 °C.
After euthanizing the animals by cervical dislocation, the entire intestine was
harvested and the small intestine, colon, and cecum were isolated.
Determination of fecal bacterial load. Stool samples were collected on the third
day after treatment by gavage with a mix of antibiotics or placebo. Fifty milligrams
of the samples were used for extraction of the microbial genomic DNA using the
InvitrogenTM PureLinkTM Microbiome DNA Purification kit (Thermo Fisher
Scientific, MA, USA). Bacterial DNA was quantified by real-time PCR using pri-
mers complementary to 16S rDNA of Eubacteria (sense ACT CCT ACG GGA
GGC AGC AGT; anti-sense ATT ACC GCG GCT GCT GGC)40. To determine the
fecal bacterial load, a standard curve with serial dilutions was employed using
genomic DNA extracted from Escherichia coli grown in vitro. Results obtained
were normalized by the control condition (untreated mice).
SCFA measurements. Colonic luminal content samples were weighed into 1.5 ml
tubes, crushed and homogenized in 100 µl of distilled water. Subsequently, 40 mg of
sodium chloride, 20 mg of citric acid, 40 µl of 1 M hydrochloric acid, and 200 µl of
butanol were added. The tubes were vortexed for 2 min and centrifuged at 18,000×g
for 15 min. The supernatant was transferred to microtubes, and 1 µl was injected
into the gas chromatograph. For serum measurements, 20 mg of sodium chloride,
10 mg of citric acid, 20 µl of 1 M hydrochloric acid, and 100 µl of butanol were
added to 100 µl of serum samples. Tubes were vortexed and centrifuged as pre-
viously described and 1 µl was injected into the gas chromatograph. To quantify
SCFAs, a calibration curve for the concentration range of 0.015–1 mg/ml was
constructed. SCFAs measurements were performed following a recently published
protocol41: chromatographic analyses were performed using an Agilent 6850 sys-
tem with ExChrom software, equipped with a 7683B automatic liquid sampler, a
flame ionization detector (FID) (Agilent Technologies, USA), and a fused-silica
capillary RTX-WAX (Restec Corporation, U.S.) with dimensions of 60 m × 0.25
mm internal diameter (i.d.) coated with a 0.15-µm thick layer of polyethylene
glycol. The initial oven temperature was 100 °C (hold 2 min), which was increased
to 200 °C at a rate of 15 °C/min (hold 5 min). The FID temperature was maintained
at 260 °C, and the flow rates of H2, air, and the make-up gas N2 were 35, 350, and
25 ml/min, respectively. Sample volumes of 1 µl were injected at 260 °C using a split
ratio of approximately 25:1. Nitrogen was used as the carrier gas at 25 ml/min. The
runtime for each analysis was 12.95 min.
Small intestinal and colon epithelium extraction. Animals were sacrificed by
cervical dislocation or exposure to CO2. Dissected small intestines and colons were
opened longitudinally and washed three times with ice cold Hank's balanced salt
solution without Ca2+/Mg2+ (HBSS). Intestinal and colon epithelium were dis-
sociated with 30 mM EDTA/HBSS on ice with shaking for 30 min for small
intestine and 1 h for colon; 50 ml Falcon tubes containing the tissue were then
shaken vigorously by hand (2–3 shakes/second) for 5 min. The colon epithelium
was incubated for an additional 10 min on ice in 30 mM EDTA/HBSS and further
shaken for 5 min. Mucus and sub-mucosa were removed by dripping the material
through a 100 μm followed by a 70 μm cell strainer. The extracted cells were
pelleted at 475×g at 4 °C for 10 min. The cells were washed with ice cold HBSS and
re-pelleted as above for further use. For the H3K18cr ChIP, three colons were
combined.
Purification and enzymatic digestion of histones. For isolating a crypt-enriched
fraction, villi were removed by shaking the small intestine pieces for 10 s after
incubation for 5 min on ice in HBSS–30 mM EDTA and before the additional
incubation in HBSS–30 mM EDTA for 15 min. Histones were then acid extracted
following a protocol published in ref. 42: one small intestine/colon was used per
extraction followed by MS analysis. Small intestine epithelium, colon epithelium,
and a crypt-enriched fraction were homogenized in lysis buffer (10% sucrose; 0.5
mM EGTA, pH 8.0; 15 mM NaCl; 60 mM KCl; 15 mM HEPES; 0.5% Triton; 0.5
mM PMSF; 1 mM DTT; 5 mM NaF; 5 mM Na3VO4; 5 mM Na-butyrate, cocktail of
protease inhibitors (Sigma)). Nuclei were separated from the cytoplasm by cen-
trifugation on sucrose cushions, washed in cold PBS, and then extracted in 0.4 N
HCl overnight (o.n.) at 4 °C. Core histones, together with linker histones protein,
were dialyzed against 100 mM ice-cold acetic acid. The concentration of purified
samples was measured using the Bradford protein assay. Approximately 10 µg were
separated on SDS-PAGE and bands corresponding to the histones H3 were excised
and in-gel digested43. Briefly, gel bands were cut in pieces and destained with
repeated washes in 50% acetonitrile (ACN) in H2O, alternated with dehydration
steps in 100% ACN. Gel pieces were then in-gel chemically alkylated by incubation
with D6-acetic anhydride (Sigma 175641) in 1M NH4HCO3 and CH3COONa
solution as catalyzer. After 3 h at 37 °C with high shaking in a thermomixer,
chemically modified gel slices were washed with NH4HCO3, alternated with ACN
Fig. 5 H3K18cr and H3K18ac ChIP-seq on MS275-treated HCT116 cells. a Probe trendplot over TSS (±10 kbp) of reads from H3K18ac and H3K18cr ChIP-
seq on HCT116 cells with and without MS275 treatment; b H3K18cr and H3K18ac ChIP-seq analysis shows a relative decrease in these marks over TSS
upon MS275 treatment, error bars are SEM, n= 3, p< 0.05, paired t-test; c aligned probe plots over TSS (±5 kbp) of reads from H3K18ac and H3K18cr
ChIP-seq with and without MS275 treatment, aligned probes were ranked according to read counts in the H3K18cr/MS275 ChIP-seq. d Scatterplot of read
counts of H3K18ac versus H3K18cr MACS peaks of control (vehicle treated) cells and e of H3K18ac versus H3K18cr MACS peaks of MS275-treated cells. f
Read counts in H3K18cr MACS peaks from control cells versus MS275-treated cells. MACS peaks close (+2 kbp) and within upregulated genes are in red. g
Read counts in H3K18ac MACS peaks from control cells versus H3K18ac, MACS peaks of MS275-treated cells, MACS peaks close (+2 kbp) and within
upregulated genes are in red. MACS peaks that show an increase in H3K18cr (f) or H3K18ac (g) on MS275 treatment are in blue. For both H3K18cr and
H3K18ac, there is a disproportionate larger number of MACS peaks linked to MS275-upregulated genes that also show an increase in H3K18cr (f) or
H3K18ac (g) on MS275 treatment compared to those that show a decrease in these modifications (p< 0.0001, χ2 test)
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at increasing percent (from 50 to 100%). In-gel digestion was performed with 100
ng/µl trypsin (Promega V5113) in 50 mM NH4HCO3 at 37 °C overnight. Chemical
acetylation occurs on unmodified and monomethylated lysines and prevents
trypsin digestion at these residues, thus producing a pattern of digestion similar to
that obtained with the Arg-C protease (the so-called “Arg-C like” in-gel digestion
pattern). The resulting histone peptides display an optimal length for MS detection
and enhanced hydrophobicity that increases their separation at ultra-pressure
chromatographic regimes.
Finally, digested peptides were collected and extracted using 5% formic acid
alternated with ACN 100%. Digested peptides were desalted and concentrated
using a combination of reverse-phase C18/C “sandwich” system and strong cation
exchange (SCX) chromatography on hand-made micro-columns (StageTips44, 45).
Eluted peptides were lyophilized, suspended in 1% TFA in H2O, and then subjected
to LC-MS/MS.
LC-MS/MS. The peptide mixtures were analyzed by online nano-flow LC-MS/MS
using an EASY-nLC 1000 (Thermo Fisher Scientic) connected to a QExactive
(Thermo Fisher Scientific) through a nano-electrospray ion source. The nano-LC
system was operated in one column setup with a 25-cm analytical column (75 µm
inner diameter, 350 µm outer diameter) packed with C18 resin (ReproSil, Pur
C18AQ 1.9 m, Dr. Maisch, Germany) configuration. Solvent A was 0.1% formic
acid (FA) in ddH2O and solvent B was 80% ACN with 0.1% FA. Samples were
injected in an aqueous 1% TFA solution at a flow rate of 500 nl/min. Peptides were
separated with a gradient of 0–40% solvent B for 100 min, followed by a gradient of
40–60% in 5 min, and 60–95% over 5 min at a flow rate of 250 nl/min. The Q-
Exactive instrument was operated in the data-dependent acquisition (DDA) to
automatically switch between full scan MS and MS/MS acquisition. Survey full scan
MS spectra (from m/z 300–1150) were analyzed in the Orbitrap detector with
resolution R = 60,000 at m/z 200. The 10 most intense peptides were sequentially
isolated to a target value of 3 × 106 and fragmented by high-energy collisional
dissociation (HCD) with a normalized collision energy setting of 27%. The max-
imum allowed ion accumulation times were 20 ms for full scans and 50 ms for MS/
MS and the target value for MS/MS was set to 1 × 106. Standard mass spectrometric
conditions for all experiments were as follows: spray voltage, 2.4 kV; no sheath and
auxiliary gas flow.
MS data analysis and relative abundance profiling. Acquired RAW data were
analyzed by MaxQuant(MQ) software v1.5.2.8, using the Andromeda search
engine46. Uniprot Mouse database (70,902 entries) was used for peptide identifi-
cation. Enzyme specificity was set to Arg-C. Estimated false discovery rate of all
peptide identifications was set at a maximum of 1% (Decoy database-based
approach). Mass tolerance for searches was set to a maximum of 6 parts per million
(ppm) for peptide masses and 20 ppm for HCD fragment ion masses. A maximum
of three missed cleavages was allowed. In the search, we focused on lysine
methylation and acylation, including as variable modifications: D3-acetylation
(+45.0294 Da), D3-acetylation (+45.0294 Da) plus monomethylation (+14.016 Da),
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dimethylation (+28.031 Da), trimethylation (+42.046 Da), acetylation (+42.010
Da), and crotonylation (+68.074 Da). The use of high-accuracy criteria for HCD
fragment ions tolerance (20 ppm) guarantee the capability to discriminate among
other possible forms of acylation (e.g., lysine butyrylation (70.0418 Da) and β-
hydroxybutyrylation (86.0367 Da)), therefore they were not included in the search.
MaxQuant search results were exported and peptides with Andromeda score <60
and localization probability score <0.75 were removed. Filtered data were subjected
to manual inspection and validation using the viewer.exe module integrated in MQ
software47. Extracted ion chromatograms were constructed for each precursor
based on the m/z value, using a mass tolerance of 10 ppm with a mass precision up
to four decimals. For each histone-modified peptide, the relative abundance per-
centage (RA%) was estimated by dividing the area under the curve (AUC) of each
modified peptide over the sum of the areas corresponding to all observed isoforms
of that peptide, including the unmodified forms48. Significant changes among crypt
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HDAC1 and crotonate assay is representative of two western blots
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and colon versus small intestine fraction have been calculated with a two-way
ANOVA test using the Perseus software49. p-Value< 0.01 (1% FDR) were con-
sidered as significant.
Antibodies and western blot analysis. Anti-lysine crotonyl antibody (PTM-501,
1:5000), anti-crotonyl-histone H3 lys18 (anti-H3K18cr, PTM-517, 1:5000), and
anti-butyryl-histone H3 lys18 (anti-H3K18bt, PTM-306, 1:5000) were from PTM
BIOLABS; anti-tri-methyl H3 lys4 antibody was from Active Motif (anti-
H3K4me3, Cat.39159); anti-crotonyl-histone H4 lys8 antibody (anti-H4K8cr,
ab201075), anti-acetyl-histone H3 lys18 (anti-H3K18ac, ab1191, 1:10000), anti-
histone H4 (ab31827, 1:40000) anti-histone H3 (ab1791, 1:40000), and anti-
LaminB1 (ab16048, 1:5000) were from Abcam; mouse monoclonal anti-HDAC1
(Clone 2E10, 1:5000) from Millipore, monoclonal anti-HDAC2 (C-8) (sc9959,
1:5000) from SantaCruz, and mouse polyclonal HDAC3 (BD61124, 1:5000) from
BD biosciences.
Western blots were washed with tris-borate-sodium-0.05% Tween-20 (TBS-T)
and developed using enhanced chemiluminescence (ECL); uncropped western blots
are shown in Supplementary Figures 12–14.
Cryosections and immunofluorescence staining. Cryosections were prepared
from adult murine tissue, fixed for 90 min at RT with 4% formaldehyde in phos-
phate buffered saline (PBS). After 2 × 5 min washes with 1× PBS, samples were
incubated in 30% sucrose overnight at 4 °C and embedded in Cryomatrix (Ther-
moFisher 6769006). Frozen blocks were cut with the Leica CM1860 cryotome to 8
μm sections and attached to Superfrost Plus slides (ThermoFisher 4951PLUS4).
Before staining, sections were brought to RT, dried for 3 min at 60 °C, permeabi-
lized for 20 min at RT in 1% Triton-X-100/PBS, and unmasked for 30 min at 95 °C
in a citrate based-unmasking buffer (VECTOR H3300) followed by 3 × 5min
washes in PBS. Slides were blocked for 1 h in 5% FBS/PBS (FBS: fetal bovine
serum) at RT followed by primary antibody (pan-crotonyl PTM Biolabs Inc.
#PTM501, 1 µg/ml final conc.) incubation in blocking solution for 1 h at RT. After
4 × 5 min washes in 1× PBS, secondary antibody (AlexaFluor 488 Invitrogen
A11008, 1 µg/ml final conc.) was applied for 1 h at RT in blocking solution sup-
plemented with DAPI. After 4 × 5 min washes in 1× PBS, samples were mounted in
Vectashield H-1000 and sealed. Controls without the primary antibody were
processed accordingly. Imaging was performed with the Zeiss780 confocal
microscope using 20× air and 63× oil immersion objectives at optimal resolution
settings. Z-stacks of whole sections were imaged and further processed to max-
imum projections with ImageJ software. For optimal print results background
correction and contrast enhancement with up to 3% pixel saturation were per-
formed with ImageJ.
Cell culture and cell cycle analysis. Human colon carcinoma cells (HCT116)
were a gift from Simon Cook's lab (Babraham Institute) who obtained them from
Bert Vogelstein, John Hopkins University, Baltimore. This cell line is not in the
database of commonly misidentified cell lines (ICLAC). They were grown in
DMEM media containing glucose and pyruvate, 10% FBS, 2 mM L-glutamine, 100
units/ml penicillin, and 100 µg/ml streptomycin. For the cell cycle analysis,
HCT116 cells were blocked at G1 with 15 nM of abemaciclib (LY2835219, Seleck
Chemicals) for 48 h and released by washing 2× with PBS and adding fresh
medium. Class I HDAC inhibition was with 5 μM MS275 for 48 h. Cells were
washed 2× with PBS and fresh medium supplemented with 1 μM MS275 was
added. Cells were harvested at indicated intervals after release and one half was
analyzed by western blotting. The remainder were used to determine cell cycle
profiles with propidium iodide staining using the BD Pharmingen PI/RNAse
staining buffer on LSRII Flow Cytometer (BD Biosciences) and Cell Cycle tool on
FlowJo 10.0.8. HDAC1 over-expression was performed by transfecting HCT116
cells using Lipofectamine® 2000 Transfection Reagent following manufacturer's
protocol using 50 μL of reagent and 12 μg of p181 pK7-HDAC1 (GFP) plasmid
DNA (gift from Ramesh Shivdasani, Addgene plasmid # 1105450) or an N-terminal
deletion mutant in a 60-mm dish for 16 h.
Whole cell extract preparations. For whole cell extract preparation, cells were
detached with trypsin, washed in PBS, and boiled in Laemmli sample buffer
(Biorad) for 5 min. The extracts were briefly sonicated to remove high molecular
weight DNA before loading on an SDS-polyacrylamide gel for electrophoresis.
Intestinal organoid seeding and cultures. Small intestinal crypts were derived
from wildtype C57BL/6 mice using a slightly modified protocol from reference51.
In brief, collected small intestines were opened longitudinally and the majority of
villi removed by gentle scraping with a coverslip. The tissue was cut to 3–5 mm
pieces, washed five times with cold PBS, and vigorous shaking. After 30 min
incubation on ice with 2 mM EDTA/ PBS, the remaining villi were removed with
short shaking and tissue pieces were incubated for additional 30 min in 5 mM
EDTA/PBS on ice. After another short shake, crypts were passed through a 40-μm
cell strainer and pelleted at 425×g 1500 rpm at 4 °C for 10 min. The pellet was
washed with cold PBS and 100–200 crypts were suspended in 50 μl Red-phenol-
free Matrigel (BD Biosciences) droplets. After polymerization, complete medium
containing advanced DMEM/F12 (Sigma), 2 mM Glutamax (Invitrogen), 10 mM
HEPES (Gibco), 100 U/ml penicillin/streptomycin (Invitrogen), 1 mM N-acetyl-
cysteine (Sigma), 1× B27 supplement (Invitrogen), 1× N2 supplement (Invitrogen),
50 ng/ml mouse EGF (Peprotech), 100 ng/ml mouse Noggin (Peprotech), and 10%
human R-spondin-1-conditioned medium from R-spondin-1-transfected
HEK293T cells (Cultrex) was added to the cultures. Medium was changed every
3 days and organoids passaged after 7–10 days.
ChIP-seq of extracted colon epithelium. The colon epithelium cell pellet was
resuspended in 10 ml of PBS-1% formaldehyde and fixation was carried out for 10
min, at RT with gentle agitation. The reaction was quenched by the addition of
glycine (0.125M final concentration) and the cells were pelleted at 475×g at 4 °C
for 10 min, washed once with PBS, re-pelleted and either snap-frozen in liquid
nitrogen for storage at −80 °C or processed further immediately. The cell pellet was
resuspended and incubated for 10 min in 500 μl 50 mM Tris-HCl, pH 8.0, 10 mM
EDTA 1% SDS (ChIP lysis buffer) on ice. Sonication of the chromatin to 100–500
bp fragment size range in polystyrene tubes was performed with a water-cooled
Bioruptor (Diagenode), high power, 4 °C, 12 cycles, 30 s on, 30 s off. The sonicated
material was transferred to a 1.5-ml tube, incubated for 30–45 min on ice, and
pelleted at 20,800×g for 10 min, 4 °C to precipitate SDS. We pooled three colons to
perform three ChIP experiments, using 20–25 μg equivalent of DNA for each
experiment. For immunoprecipitation, the chromatin was diluted 1:10 with ChIP
dilution buffer (16.7 mM Tris-HCl, pH 8.0, 1.2 mM EDTA, 167 mM NaCl, 1.1%
Triton-X-100), 5 μg anti-H3K18cr antibody (PTM-517) or H3K4me3 antibody
(Active Motif Cat.39159) per 20 μg DNA was added and this was incubated
overnight on a rotating wheel at 4 °C. One percent input chromatin was collected
and kept on ice. Immunoprecipitation of chromatin complexes was with Protein A-
coated Dynabeads (Novex, Cat.10001D); 20–30 μl of bead suspension were washed
two times with ChIP dilution buffer and the antibody–chromatin mix was added to
the beads. Immunoprecipitation was for 2 h at 4 °C on a rotating wheel. Following
this incubation, tubes were spun briefly and bound material was separated from
unbound using a magnetic stand on ice.
All washes were performed at 4 °C for 5 min on a rotating wheel using 20×
volumes with respect to the beads volume used. Beads were washed 1× with low-
salt wash buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 150 mM NaCl, 1%
Triton-X-100, 0.1 % SDS), 2× with high-salt wash buffer (20 mM Tris-HCl, pH 8.0,
2 mM EDTA, 500 mM NaCl, 1% Triton-X-100, 0.1 % SDS), and 1× with 10 mM
Tris-HCl, 1 mM EDTA (1× TE). Elution of DNA from beads was with 200 μl of
freshly prepared elution buffer (0.1 M NaHCO3, 1% SDS) at 65 °C for 30 min in a
thermomixer at 1000 rpm. Supernatant was separated using a magnetic stand and
transferred to a fresh tube. After bringing all inputs to 200 μl with elution buffer,
both chromatin and input samples were reverse cross-linked by adding 8 μl of 5 M
NaCl followed by an incubation at 65 °C overnight at 300 rpm in a thermomixer.
Proteinase K Solution (Ambion, Cat:AM2548) was added to samples to a final
concentration of 0.25 mg/ml and incubated for 2 h at 65 °C, 300 rpm. Chipped
DNA was purified with QIAquick PCR purification kit (Qiagen, Cat.28104) and
quantified using QubitTM 3.0 fluorimeter. Library preparation was performed from
5 ng of purified DNA using the NEBNext® UltraTM II DNA Library Prep Kit for
Illumina® with the following modifications: Illumina Tru-Seq adaptors were used
and library amplification was performed with the KAPA PCR Amplification kit
(KAPA, Cat. KK2501) using 11 cycles. Libraries were sequenced on a
HiSeq2500 sequencer (Illumina) according to manufacturer's instructions.
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Fig. 8 BOC-Lys(crotonyl)-AMC inhibits deacetylation by HDAC1. A
fluorometric in vitro assay showing that HDAC1 efficiently deacetylates the
BOC-Lys(acetyl)-AMC substrate alone, but not in the presence of same
amounts of BOC-Lys(crotonyl)-AMC. Performed in triplicate, error bars are
standard deviation
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ChIP-seq and ChIP-qPCR of HCT116 cell extracts. HCT116 cells were treated
with either 5 µM MS275 or DMSO for 18 h. Cells were trypsinized and fixed as
indicated in the ChIP-seq section above. Fixed cells were re-suspended in Soni-
cation buffer (150 mM NaCl, 25 mM Tris pH 7.4, 5 mM EDTA, 0.1% Triton, 1%
SDS complemented with 10 mM sodium butyrate and protease inhibitor cocktail
(P8340, Sigma)) and sonicated as described above for 15 cycles. After centrifuga-
tion at 14,000×g for 10 min, supernatant was diluted 10× in ChIP dilution buffer;
1% input chromatin was collected and kept on ice and 30 µg equivalent of DNA per
sample was incubated overnight on a rotating wheel at 4 °C with 5 µg of anti-
H3K18cr antibody (PTM-517, PTM Biolabs) or 0.3 µg of anti-H3K18ac antibody
(ab1191, Abcam). Twenty microliters of Magnetic ProtA/G Beads (Millipore) were
added to the samples and incubated on a rotating wheel for 3 h at 4 °C. Antibody-
bound beads were washed as described above. Chip DNA was eluted at 65 °C for
30 min in 200 µl of elution buffer. De-crosslinking and DNA elution of both ChIP
and input samples was performed as described in the ChIP-seq section. Real
time qPCR analysis was carried out on input and ChIP DNA samples using the
SYBR® Green PCR Master Mix (Applied Biosystems) and run on a BioRad CFX96
qPCR system. Each experiment has been carried out two times (biological repli-
cates) and each sample has been run in triplicate (technical replicate). One percent
of starting chromatin was used as input and data were analyzed accordingly.
Primers were used at a final concentration of 250 nM with 62 °C as annealing/
extension temperature and are listed in Table 2.
RNA-seq. RNA was extracted from both HCT116 cells (four biological replicates)
and mouse colon epithelium (three mice as biological replicates) using the RNeasy
Plus Mini Kit (Qiagen), following the manufacturer's instructions. Extracted RNA
was quantified with Nanodrop and the quality assessed on a Bioanalyzer (Agilent).
Library preparation was performed from 500 ng of RNA using the NEB Next®
UltraTM Directional RNA Library Prep Kit for Illumina® and the NEBNext® Poly
(A) mRNA magnetic isolation module. Illumina Tru-Seq adaptors were used and
library amplification was performed with the KAPA PCR Amplification kit (KAPA,
Cat. KK2501) using 14 cycles. Libraries were sequenced on a HiSeq2500 sequencer
(Illumina) according to the manufacturer's instructions.
Bioinformatic analysis. RNA-seq: Sequencing reads were adaptor trimmed using
Trim Galore! (version 0.4.2) and mapped to the mouse (GRCm38/mm10) refer-
ence genome with HiSat2 (version 2.0.5). Analysis of RNA-seq data was performed
with SEQMONK version 1.36.0 on filtered reads with a MAPQ score of >60 for
uniquely mapped reads. Read counts were quantified using the RNA-seq quanti-
tation pipeline implemented in Seqmonk, quantifying only probes with at least one
read. Probe read values were corrected for transcript length and divided into
percentile bins according to their average expression levels of three replicates.
ChIP-seq analysis: For mouse colon and HCT116 H3K18cr, two replicates and
for H3K4me3 three biological replicates were used. Sequencing reads were adaptor
trimmed using Trim Galore! (version 0.3.8 and 0.4.2) and mapped to the mouse
(GRCm38/mm10) or human (GRCh38) reference genomes with Bowtie2 (version
2.0.4.). Analysis of ChIP-seq data was performed with SEQMONK version 1.36.0
on filtered reads with a MAPQ score of >42, duplicate reads were always removed.
For Fig. 2b, the genome was segmented in 1000 bp non-overlapping 'probes' and
read counts were quantified for each probe and normalized to the largest datastore.
For Fig. 2c, H3K4me3 peaks were identified using the MACS peak finder
embedded in the SEQMONK program with the ChIP-seq data of H3K4me3 from
colon epithelial cells and INPUT as reference. Selected fragment size was 300 bp
and p-value significance threshold was 10−5. Reads were quantitated in and ±5 kbp
around the MACS peaks. For Fig. 2d, read counts were quantified over the TSS
(using a window of ±1 kb upstream of genes) and probes that had more than 100
reads in input were removed in both input and ChIP. For Fig. 2e, read counts were
quantified over the TSS (using a window of ±0.5 kb upstream of transcripts) and
were overlapped with RNA-seq data. KEGG pathway analysis was with DAVID 6.8
with electronic annotations excluded.
ChIP-qPCR data analysis. Prior to analysis, a logarithmic transformation of the
data was carried out. Subsequently, we carried out a two-way ANOVA test fol-
lowed by Holm-Sidak's multiple comparison test. Data were analyzed using the
Graphpad Prism Software.
In vitro enzymatic assays of histone decrotonylation and deacetylation.
Recombinant human histone H3.1 (NEB) was acetylated or crotonylated in vitro
using the recombinant catalytic domain of p300 (human, ENZO) in presence of
acetyl-CoA or crotonyl-CoA (Sigma-Aldrich), respectively. The reaction was car-
ried out with 5.65 μM histone H3.1 and 0.66 μM P300 catalytic domain in 50 mM
Tris-HCL pH 8, 50 mM KCl, 0.1 mM EDTA, 0.01 % Tween-20, 10% glycerol, 1
mM DTT, and 87 μM crotonyl-CoA or acetyl-CoA at 30 °C for 2 h. The reaction
was stopped by heating at 65 °C for 5 min and the histones were diluted with two
volumes of HDAC buffer (25 mM Tris-HCl, pH 7.5, 50 mM KCl, 1 mM MgCl2, 1
μM ZnSO4) for either decrotonylation or deacetylation reactions. Decrotonylation/
deacetylation was typically performed with 1.75 μMmodified histones and 0.12 μM
HDAC1 (recombinant, human, Active Motif) or 0.18 μM HDAC2 (recombinant,
human, ABCAM) at 30 °C for 2 h. Recombinant HDAC3/Ncor1 complex was from
ENZO Life Sciences. All HDACs were produced in insect cells and purified. After
the reaction, the histone modifications were identified by western blot. The pixel
intensities of the western blot bands were quantified with the Image J software.
For the enzyme kinetic analysis, histone H3 was acetylated or crotonylated
in vitro as described above. Dot blot western analysis with synthetic H3 peptides
that were specifically crotonylated or acetylated at K18 indicated full crotonylation
and acetylation of the histone H3 at K18 under these conditions, therefore, we
assume that the histone had been fully crotonylated or acetylated. Different
dilutions of modified histones were prepared in HDAC buffer (25 mM Tris-HCl,
pH 7.5, 50 mM KCl, 1 mM MgCl2, 1 μM ZnSO4) for either decrotonylation or
deacetylation reactions. Decrotonylation/deacetylation was performed with 1.41 to
0.19 μM modified histone H3 and 0.03 μM HDAC1 (recombinant, human, Active
Motif) at 30 °C and stopped at 95 °C for 1 min. Five different modified histone
concentrations and five different time points were performed in triplicate for the
decrotonylation and deacetylation reactions.
Each reaction was spotted in quadruplicate and left to dry before being rinsed
with transfer buffer and TBS-T. Western blot was performed using anti-H3K18ac
and anti-H3K18cr antibodies. Spots were quantified using image J and spot
intensity was converted to substrate concentration by multiplying each relative
value by the concentration of modified histone in the reaction mix. Substrate
concentration against time were plotted for each histone concentration and a linear
regression was fitted for the first 30 s to 1 min of the reaction, as appropriate. The
rate of each reaction set was plotted as replicates against substrate concentration.
GraphPad Prism Version 7 software was used to calculate Km, Vmax, and Kcat.
Colorimetric deacetylation assay. Synthesis of BOC-Lys(acetyl)-AMC and BOC-
Lys(crotonyl)-AMC and the colorimetric assay was essentially as in ref. 2 with some
modifications: for the synthesis of crotonyl-N-hydroxysuccinimide, N-hydro-
xysuccinimide (149 mg, 6 equivalents, eq) was dissolved in 2.5 ml anhydrous
dichloromethane to which diisopropylethylamine (167 mg, 6 eq) was added. The
solution was cooled in an ice bath and trans-crotonoyl chloride (135 mg, 6 eq) was
added and the reaction stirred at 20 °C for 3 h. Ethyl acetate (5 ml) was added and
the solution washed with 5 ml brine, dried over magnesium sulfate and con-
centrated. The crude product was dissolved in 3 ml dry ACN and the appropriate
amount used in the next step. Acetyl-N-hydroxysuccinimide was prepared in the
same way but using acetyl chloride rather than crotonoyl chloride. For the
synthesis of BOC-Lys (crotonyl)-AMC, Boc-Lys-AMC acetate salt (100 mg, 1 eq)
purchased from Bachem AG was dissolved in 4 ml water:ACN (1:1). Sodium
bicarbonate (19.95 mg, 1.1 eq) was added in 1 ml water followed by trans-crotonyl-
N-hydroxysuccinimide ester (2 eq) in 2 ml ACN. The reaction was left for 18 h and
then concentrated to remove the ACN. The product was extracted into ethyl
acetate, dried over anhydrous magnesium sulfate and concentrated. The product
was purified on silica in dichloromethane:methanol (15:1). BOC-Lys(acetyl)-AMC
Table 2 Primers used in ChIP-qPCR
Name Feature Forward (5′→3′) Reverse (5′→3′)
up PUMA Intergenic GTTGCCAGTTACCACACCCT CCCAACTGTCCTTGCTGCTA
ADAD1 TSS of not expressed gene GCTTCAGGACGTGTGAGGTA TACCTGCGTGAGGGTTGTTT
CLDN7 TSS of expressed gene ACTCTAAGGGAGGGGAACGAT CCACTGGGACCTAAAGCCG
p21 TSS of expressed gene AGCAGGCTGTGGCTCTGATT CAAAATAGCCACCAGCCTCTTCT
PUMA TSS of expressed gene GTGTGTGTGTCCGACTGTCCCG AAGGAGGACCCAGGCGCTGT
Chr1 SAT Repetitive region TCATTCCCACAAACTGCGTTG TCCAACGAAGGCCACAAGA
Chr4 SAT Repetitive region CTGCACTACCTGAAGAGGAC GATGGTTCAACACTCTTACA
SAT1 Repetitive region GAACCTGTGTTGCTGCTTTG TTCAAAGGTACTCTGCTTGGTACA
SAT2 Repetitive region TGAATGGAATCGTCATCGAA CCATTCGATAATTCCGCTTG
NBL2 Repetitive region TCCCACAGCAGTTGGTGTTA TTGGCAGAAACCTCTTTGCT
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was prepared in the same way but using acetyl-N-hydroxysuccinimide rather than
crotonyl-N-hydroxysuccinimide.
The enzymatic reaction was set up in a 96-well plate in triplicate in a 51-μl
volume with 0.035 μM HDAC1 and 0.2 mM BOC-Lys(acetyl)-AMC/BOC-Lys
(crotonyl)-AMC in HDAC buffer (see above) at 30 °C for 2 h. After this, 5 μl of a 1
mg/ml trypsin solution in 1 mM HCl was added and the mixture was incubated 1 h
at 37 °C. Fluorescence was read with a Pherastar plate reader at 360 nm excitation/
450 nm emission.
Data availability. Next-generation sequencing data have been submitted to GEO
under accession code GSE96035. The authors declare that all other data supporting
the findings of this study are within the manuscript and its supplementary files or
are available from the corresponding authors upon request.
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